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Research letter
Daylight photodynamic therapy: patient
willingness to undertake home treatment
DOI: 10.1111/bjd.17920
DEAR EDITOR, In the U.K., almost one in four individuals over
60 years are affected by actinic keratoses (AKs),1 and this is a
cause of significant morbidity in an ageing population, with
risk of progression to squamous cell carcinoma.2 Daylight
photodynamic therapy (dPDT) is an effective and simple treat-
ment for field change AK, with similar efficacy to conventional
PDT.3 Commonly, skin surface preparation is performed in a
dermatology clinic prior to dPDT. However, a recent German
study by Karrer and colleagues investigated dPDT as a patient-
applied home-delivered treatment for face and scalp AK and
reported that patients who undertook this self-administered
treatment had high levels of efficacy, tolerance and patient
satisfaction.4
We surveyed patients who had previously received dPDT
at Ninewells Hospital, Dundee to ascertain their experience
of treatment, whether they would have liked dPDT sooner,
whether they would consider doing the treatment them-
selves and what type of support they would require
(https://www.researchgate.net/project/Smart-PDT). A ques-
tionnaire was sent to 56 patients and 35 were returned. An
engagement event was also held, inviting nine survey par-
ticipants of differing viewpoints (five attended) and six
members of staff to discuss the questionnaire further and
investigate potential service improvements (focusing on
improving the current service and the potential for home
treatment). Formal advice on the construction and content
of the questionnaire, and on the organization, content and
focus of the engagement event was provided by the
National Health Service (NHS) Tayside improvement team,
which is part of the Academic Health Science Partnership in
Tayside. Approval of the use of the questionnaire and
engagement event was obtained through the NHS Tayside
local clinical governance process.
Consistent with previous published studies,5 most respon-
dents experienced no problems during dPDT (63%) and
90% felt that clearance rates were the same as (32%) or
better than (58%) other treatments that they previously
underwent for AK. In this secondary care setting, most of
our respondents had previously received several types of
treatment prior to dPDT (61% 5-fluorouracil, 52% diclofe-
nac, 51% surgery, 45% cryotherapy, 36% imiquimod). A
total of 54% of patients reported that dPDT was better
tolerated and 27% stated similar tolerance to other AK treat-
ments; although poor weather had caused difficulties for
some (low temperature – six responses and rain – five
responses). Respondents ranked minimal pain/discomfort,
disease clearance, convenience of outdoor treatment and
good cosmetic outcome as important factors for
dPDT, with 82% being happy or very happy with the
service.
It is apparent from our results and published studies that
dPDT is a preferred and well-tolerated treatment for AKs.3 It
has also been reported that there is poor adherence with other
forms of AK treatment.1 Currently, dPDT is only available in a
limited number of locations in the U.K. and often these are
secondary healthcare providers. Our respondents would have
appreciated the opportunity to have treatment sooner in a non-
hospital setting (73%), with 12% preferring dPDT via general
practitioner surgeries, 15% could be persuaded to undertake
self-treatment, 34% said they would be happy to self-treat if
adequate support was available and 12% would like to control
and have some ownership of their own treatment.
Respondents were also asked their opinion on using a
smartphone application to perform treatment at home and the
support they would require using such an application. In total,
50% of respondents said they owned a smartphone or tablet
and in order to use the application to perform dPDT at home
78% of respondents would want contact details of a dPDT
nurse, while 61% wanted weather predictions and 61%
required a step-by-step written guide. Half of respondents
wanted the ability to send secure messages to a doctor or
nurse, 44% wanted instructional videos (i.e. prodrug applica-
tion and aftercare) and the same number required the ability
to send pictures to the doctors or nurses. Only 11% would
want audio instructions, with 17% selecting ‘other’ and high-
lighting the desire for accurate dosage reports throughout
treatment. From the engagement event it was further clarified
that it would be essential for the app to be intuitive and easy
to use. The clear message from this event was that patients
wanted choice – to have local treatment available or for self-
delivery at home.
To our knowledge, it has never previously been demon-
strated that there is a willingness within the AK patient popu-
lation to undertake dPDT treatment at home and to use smart
technology to assist in such an endeavour. Our findings high-
light the importance to patients of the availability of well-tol-
erated, effective, convenient treatment for AKs, as well as the
high value of including patient opinion in clinical service
development.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019) 1
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
L . J . MCLE L LAN1 iD
P . O’MAHONEY1 , 2 , 3 iD
S . LOGAN2
S . YUL E2
C . GOODMAN1 , 2
A . L E S AR3
L . FUL L E RTON3
S . I B BOT SON1 , 2 , 3 iD
E . EAD I E 2 , 3 iD
1School of Medicine, University of Dundee,
Dundee, U.K.
2The Scottish Photodynamic Therapy Centre,
and 3Photobiology Unit, NHS Tayside,
Ninewells Hospital, Dundee, U.K.
E-mail: l.j.y.mclellan@dundee.ac.uk
References
1 de Berker D, McGregor JM, Mohd Mustapa MF et al. British Associa-
tion of Dermatologists’ guidelines for the care of patients with acti-
nic keratosis 2017. Br J Dermatol 2017; 176:20–43.
2 Morton CA, Szeimies R-M, Sidoroff A, Braathen LR. European
guidelines for topical photodynamic therapy part 1: treatment deliv-
ery and current indications – actinic keratoses, Bowen’s disease,
basal cell carcinoma. J Eur Acad Dermatology Venereol 2013; 27:536–44.
3 Sotiriou E, Evangelou G, Papadavid E et al. Conventional vs. daylight
photodynamic therapy for patients with actinic keratosis on face
and scalp: 12-month follow-up results of a randomized, intra-indi-
vidual comparative analysis. J Eur Acad Dermatology Venereol 2018;
32:595–600.
4 Karrer S, Aschoff RAG, Dominicus R et al. Methyl aminolevulinate
daylight photodynamic therapy applied at home for non-hyperkerato-
tic actinic keratosis of the face or scalp: an open, interventional study
conducted in Germany. J Eur Acad Dermatology Venereol 2019; 33:661–6.
5 Cordey H, Valentine R, Lesar A et al. Daylight photodynamic therapy
in Scotland. Scott Med J 2017; 62:48–53.
Funding sources: L.J.M.’s salary is supported by an Innovate U.K.
award. The P.O.’M. and S.Y. salaries are supported by the Medical
Laser Research Fund (registered charity SC037390).
Conflicts of interest: S.I. has received honoraria and travel expenses
from Galderma and Spirit Healthcare.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019)
2 Research letter
